Brimonidine tartrate ophthalmic solution is used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Apotex is recalling six lots of Brimonidine Tartrate Ophthalmic Solution 0.15%, which is an alpha-adrenergic receptor agonist to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Cracks have been found in some of the units caps of brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility and if so, the possibility of adverse events.
The lot number and expiration date are located on the top flap of the carton and to the left side of the product description on the bottle label beside the barcode. These lots were distributed nationwide in the USA between April 05, 2022, to February 22, 2023. Lot numbers and expiration dates are listed here.
Trump Impact on Medicare Drug Price Negotiations Uncertain
Published: January 22nd 2025 | Updated: January 22nd 2025Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Read More